Cargando…
Chotosan ameliorates cognitive and emotional deficits in an animal model of type 2 diabetes: possible involvement of cholinergic and VEGF/PDGF mechanisms in the brain
BACKGROUND: Diabetes is one of the risk factors for cognitive deficits such as Alzheimer’s disease. To obtain a better understanding of the anti-dementia effect of chotosan (CTS), a Kampo formula, we investigated its effects on cognitive and emotional deficits of type 2 diabetic db/db mice and putat...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3564934/ https://www.ncbi.nlm.nih.gov/pubmed/23082896 http://dx.doi.org/10.1186/1472-6882-12-188 |
_version_ | 1782258387691503616 |
---|---|
author | Zhao, Qi Niu, Yimin Matsumoto, Kinzo Tsuneyama, Koichi Tanaka, Ken Miyata, Takeshi Yokozawa, Takako |
author_facet | Zhao, Qi Niu, Yimin Matsumoto, Kinzo Tsuneyama, Koichi Tanaka, Ken Miyata, Takeshi Yokozawa, Takako |
author_sort | Zhao, Qi |
collection | PubMed |
description | BACKGROUND: Diabetes is one of the risk factors for cognitive deficits such as Alzheimer’s disease. To obtain a better understanding of the anti-dementia effect of chotosan (CTS), a Kampo formula, we investigated its effects on cognitive and emotional deficits of type 2 diabetic db/db mice and putative mechanism(s) underlying the effects. METHODS: Seven-week-old db/db mice received daily administration of CTS (375 – 750 mg/kg, p.o.) and the reference drug tacrine (THA: 2.5 mg/kg, i.p.) during an experimental period of 7 weeks. From the age of 9-week-old, the animals underwent the novel object recognition test, the modified Y-maze test, and the water maze test to elucidate cognitive performance and the elevated plus maze test to elucidate anxiety-related behavior. After completing behavioral studies, Western blotting and immunohistochemical studies were conducted. RESULTS: Compared with age-matched non-diabetic control strain (m/m) mice, db/db mice exhibited impaired cognitive performance and an increased level of anxiety. CTS ameliorated cognitive and emotional deficits of db/db mice, whereas THA improved only cognitive performance. The phosphorylated levels of Akt and PKCα in the hippocampus were significantly lower and higher, respectively, in db/db mice than in m/m mice. Expression levels of the hippocampal cholinergic marker proteins and the number of the septal cholinergic neurons were also reduced in db/db mice compared with those in m/m mice. Moreover, the db/db mice had significantly reduced levels of vasculogenesis/angiogenesis factors, vascular endothelial growth factor (VEGF), VEGF receptor type 2, platelet-derived growth factor-B, and PDGF receptor β, in the hippocampus. CTS and THA treatment reversed these neurochemical and histological alterations caused by diabetes. CONCLUSION: These results suggest that CTS ameliorates diabetes-induced cognitive deficits by protecting central cholinergic and VEGF/PDGF systems via Akt signaling pathway and that CTS exhibits the anxiolytic effect via neuronal mechanism(s) independent of cholinergic or VEGF/PDGF systems in db/db mice. |
format | Online Article Text |
id | pubmed-3564934 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2012 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-35649342013-02-08 Chotosan ameliorates cognitive and emotional deficits in an animal model of type 2 diabetes: possible involvement of cholinergic and VEGF/PDGF mechanisms in the brain Zhao, Qi Niu, Yimin Matsumoto, Kinzo Tsuneyama, Koichi Tanaka, Ken Miyata, Takeshi Yokozawa, Takako BMC Complement Altern Med Research Article BACKGROUND: Diabetes is one of the risk factors for cognitive deficits such as Alzheimer’s disease. To obtain a better understanding of the anti-dementia effect of chotosan (CTS), a Kampo formula, we investigated its effects on cognitive and emotional deficits of type 2 diabetic db/db mice and putative mechanism(s) underlying the effects. METHODS: Seven-week-old db/db mice received daily administration of CTS (375 – 750 mg/kg, p.o.) and the reference drug tacrine (THA: 2.5 mg/kg, i.p.) during an experimental period of 7 weeks. From the age of 9-week-old, the animals underwent the novel object recognition test, the modified Y-maze test, and the water maze test to elucidate cognitive performance and the elevated plus maze test to elucidate anxiety-related behavior. After completing behavioral studies, Western blotting and immunohistochemical studies were conducted. RESULTS: Compared with age-matched non-diabetic control strain (m/m) mice, db/db mice exhibited impaired cognitive performance and an increased level of anxiety. CTS ameliorated cognitive and emotional deficits of db/db mice, whereas THA improved only cognitive performance. The phosphorylated levels of Akt and PKCα in the hippocampus were significantly lower and higher, respectively, in db/db mice than in m/m mice. Expression levels of the hippocampal cholinergic marker proteins and the number of the septal cholinergic neurons were also reduced in db/db mice compared with those in m/m mice. Moreover, the db/db mice had significantly reduced levels of vasculogenesis/angiogenesis factors, vascular endothelial growth factor (VEGF), VEGF receptor type 2, platelet-derived growth factor-B, and PDGF receptor β, in the hippocampus. CTS and THA treatment reversed these neurochemical and histological alterations caused by diabetes. CONCLUSION: These results suggest that CTS ameliorates diabetes-induced cognitive deficits by protecting central cholinergic and VEGF/PDGF systems via Akt signaling pathway and that CTS exhibits the anxiolytic effect via neuronal mechanism(s) independent of cholinergic or VEGF/PDGF systems in db/db mice. BioMed Central 2012-10-20 /pmc/articles/PMC3564934/ /pubmed/23082896 http://dx.doi.org/10.1186/1472-6882-12-188 Text en Copyright ©2012 Zhao et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Article Zhao, Qi Niu, Yimin Matsumoto, Kinzo Tsuneyama, Koichi Tanaka, Ken Miyata, Takeshi Yokozawa, Takako Chotosan ameliorates cognitive and emotional deficits in an animal model of type 2 diabetes: possible involvement of cholinergic and VEGF/PDGF mechanisms in the brain |
title | Chotosan ameliorates cognitive and emotional deficits in an animal model of type 2 diabetes: possible involvement of cholinergic and VEGF/PDGF mechanisms in the brain |
title_full | Chotosan ameliorates cognitive and emotional deficits in an animal model of type 2 diabetes: possible involvement of cholinergic and VEGF/PDGF mechanisms in the brain |
title_fullStr | Chotosan ameliorates cognitive and emotional deficits in an animal model of type 2 diabetes: possible involvement of cholinergic and VEGF/PDGF mechanisms in the brain |
title_full_unstemmed | Chotosan ameliorates cognitive and emotional deficits in an animal model of type 2 diabetes: possible involvement of cholinergic and VEGF/PDGF mechanisms in the brain |
title_short | Chotosan ameliorates cognitive and emotional deficits in an animal model of type 2 diabetes: possible involvement of cholinergic and VEGF/PDGF mechanisms in the brain |
title_sort | chotosan ameliorates cognitive and emotional deficits in an animal model of type 2 diabetes: possible involvement of cholinergic and vegf/pdgf mechanisms in the brain |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3564934/ https://www.ncbi.nlm.nih.gov/pubmed/23082896 http://dx.doi.org/10.1186/1472-6882-12-188 |
work_keys_str_mv | AT zhaoqi chotosanamelioratescognitiveandemotionaldeficitsinananimalmodeloftype2diabetespossibleinvolvementofcholinergicandvegfpdgfmechanismsinthebrain AT niuyimin chotosanamelioratescognitiveandemotionaldeficitsinananimalmodeloftype2diabetespossibleinvolvementofcholinergicandvegfpdgfmechanismsinthebrain AT matsumotokinzo chotosanamelioratescognitiveandemotionaldeficitsinananimalmodeloftype2diabetespossibleinvolvementofcholinergicandvegfpdgfmechanismsinthebrain AT tsuneyamakoichi chotosanamelioratescognitiveandemotionaldeficitsinananimalmodeloftype2diabetespossibleinvolvementofcholinergicandvegfpdgfmechanismsinthebrain AT tanakaken chotosanamelioratescognitiveandemotionaldeficitsinananimalmodeloftype2diabetespossibleinvolvementofcholinergicandvegfpdgfmechanismsinthebrain AT miyatatakeshi chotosanamelioratescognitiveandemotionaldeficitsinananimalmodeloftype2diabetespossibleinvolvementofcholinergicandvegfpdgfmechanismsinthebrain AT yokozawatakako chotosanamelioratescognitiveandemotionaldeficitsinananimalmodeloftype2diabetespossibleinvolvementofcholinergicandvegfpdgfmechanismsinthebrain |